Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Equity Average (2016 - 2022)

Edesa Biotech's Equity Average history spans 9 years, with the latest figure at $14.4 million for Q2 2022.

  • For Q2 2022, Equity Average fell 17.72% year-over-year to $14.4 million; the TTM value through Jun 2022 reached $14.4 million, down 17.72%, while the annual FY2021 figure was $9.8 million, 93.39% up from the prior year.
  • Equity Average for Q2 2022 was $14.4 million at Edesa Biotech, up from $13.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $17.5 million in Q2 2021 and bottomed at $3.0 million in Q1 2019.
  • The 5-year median for Equity Average is $6.0 million (2020), against an average of $8.2 million.
  • The largest annual shift saw Equity Average plummeted 56.06% in 2018 before it surged 185.8% in 2021.
  • A 5-year view of Equity Average shows it stood at $3.4 million in 2018, then skyrocketed by 54.43% to $5.2 million in 2019, then skyrocketed by 38.96% to $7.3 million in 2020, then soared by 62.63% to $11.8 million in 2021, then rose by 22.26% to $14.4 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Equity Average are $14.4 million (Q2 2022), $13.8 million (Q1 2022), and $11.8 million (Q4 2021).